Form D · Biotechnology
C2N Diagnostics, LLC
St. Louis, MO · CIK 0002021597
Offering snapshot reported May 30, 2025 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 12, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 30, 2025 | Initial | $9,999,891 | No comparison | 1 | SEC filing |
| Sep 26, 2024 | Amendment | $24,999,618 | $17,499,618vs May 6, 2024 | 3 | SEC filing |
| May 6, 2024 | Initial | $7,500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547632
Source: Form D, filed May 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dr. Randall Bateman | Director |
| Dr. Joel Braunstein | Director, Executive |
| Dr. Michael Goldblatt | Director |
| Dr. David Holtzman | Director |
| Fred Miller | Director |
| Micah Onixt | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4340 Duncan Avenue
St. Louis, MO, 63110
St. Louis, MO, 63110